# A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

> **NCT03730012** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

## Interventions

- **DRUG:** gilteritinib
- **DRUG:** atezolizumab

## Key facts

- **NCT ID:** NCT03730012
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-19
- **Primary completion:** 2021-05-14
- **Final completion:** 2021-06-15
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03730012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03730012, "A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03730012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*